ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 19.13 |
| Open | 19.27 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's Range | 19.00 - 20.04 |
| 52 Week Range | 17.68 - 44.00 |
| Volume | 387,856 |
| Avg. Volume | 531,435 |
| Market Cap | 541.907M |
| Beta | 1.83 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.94 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 54.00 |
Market Realist•13 days agoA Financial Overview of Supernus Pharmaceuticals in September
In the second quarter, Supernus Pharmaceuticals (SUPN) reported net revenues of $99.5 million compared to $75.8 million in the second quarter of 2017. In the first half, Supernus Pharmaceuticals generated net revenues of $190.0 million compared to $133.4 million in the first half of 2017.
Market Realist•13 days agoSupernus Pharmaceuticals Garners 89% ‘Buy’ Ratings in September
On September 11, Supernus Pharmaceuticals (SUPN) stock closed at $48.80, up 1.99% from its closing price of $47.85 on September 10. The company’s September 11 stock price was 26.0% below its 52-week high of $61.25 on June 29. Supernus Pharmaceuticals hit its 52-week low of $33.30 on November 7, 2017.
- GlobeNewswire•13 days ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted six new employees the option to purchase an aggregate of 68,251 shares of the company’s common stock, at a per share exercise price of $22.76, the closing trading price on September 10, 2018, and restricted stock units to acquire 11,373 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- GlobeNewswire•last month
Investor Expectations to Drive Momentum within Mazor Robotics, Kinross Gold, Mimecast, DBV Technologies S.A., Adamas Pharmaceuticals, and Adverum Biotechnologies — Discovering Underlying Factors of Influence
NEW YORK, Aug. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mazor ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of ADMS earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 Adamas Pharmaceuticals Inc Earnings Call
- GlobeNewswire•2 months ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted four new employees the option to purchase an aggregate of 44,016 shares of the company’s common stock, at a per share exercise price of $24.22, the closing trading price on August 7, 2018, and restricted stock units to acquire 7,334 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- Benzinga•2 months ago
The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...
- Zacks•2 months ago
Adamas Pharmaceuticals (ADMS) Reports Q2 Loss, Tops Revenue Estimates
Adamas (ADMS) delivered earnings and revenue surprises of 10.64% and 56.17%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Adamas: 2Q Earnings Snapshot
On a per-share basis, the Emeryville, California-based company said it had a loss of $1.26. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...
- GlobeNewswire•2 months ago
Adamas Reports Second Quarter 2018 Financial Results
-GOCOVRI™ extended release capsules product sales reached $7.6 million for the second quarter-. EMERYVILLE, Calif., Aug. 02, 2018-- Adamas Pharmaceuticals, Inc. today reported financial results and pipeline ...
- ACCESSWIRE•2 months ago
Adamas Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 2, 2018 / Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 2, 2018 at 4:30 PM Eastern ...
- Benzinga•2 months ago
The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 1) Bio-Rad Laboratories, Inc. (NYSE: BIO ) CAS Medical Systems ...
- GlobeNewswire•2 months ago
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia
Adamas Pharmaceuticals, Inc. (ADMS) today announced the launch of “Dyskinesia Is A Jerk,” an integrated disease education campaign focused on raising awareness about Parkinson’s disease (PD) dyskinesia and its impact, with an educational, supportive environment where people with PD dyskinesia and their care partners may share real-life experiences, have candid conversations, and unite as a community. In the United States, PD affects close to 1 million people, and of those, between 150,000 and 200,000 people experience dyskinesia, which is different from tremors (shaking in the hands and feet) and is characterized by sudden, jerky, and uncontrollable movements in the neck/face, arms, legs, torso, or entire body that can worsen over time.
- GlobeNewswire•2 months ago
Adamas to Announce Second Quarter 2018 Financial Results and Host Conference Call on August 2, 2018
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the company will report second quarter 2018 financial results on Thursday, August 2, 2018, after market close. Subsequently, Adamas’ management team will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the financial results and provide a corporate update. The conference call can be accessed by dialing 844-215-3280 for participants in the U.S. or Canada and 484-747-6383 for international callers.
Market Realist•2 months agoWhy Reata Pharmaceuticals’ Stock Price Is Skyrocketing Today
Today, Reata Pharmaceuticals is trading at a stock price of $75.00, which represents a ~61.67% hike from yesterday’s close of $46.4. On July 20, Reata Pharmaceuticals closed at $46.4, which represents ~140% growth from its 52-week low of $19.31 on March 29. Also today, Reata Pharmaceuticals hit a 52-week high of $76.25.
- GlobeNewswire•3 months ago
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (ADMS) today announced that the compensation committee of the company’s board of directors granted two new employees the option to purchase an aggregate of 29,531 shares of the company’s common stock, at a per share exercise price of $25.74, the closing trading price on July 9, 2018, and restricted stock units to acquire 4,921 shares of the company’s common stock. The stock options and restricted stock units vest over four years and were granted pursuant to the Adamas Pharmaceuticals, Inc. 2016 Inducement Plan, which was approved by the company's board of directors in March 2016 under Rule 5653(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the company.
- ACCESSWIRE•3 months ago
Free Technical Research on Akorn and Three More Generic Drugs Equities
WallStEquities.com has selected the following Generic Drugs stocks for review today: Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), Agile Therapeutics Inc. (NASDAQ: AGRX), Akorn Inc. (NASDAQ: AKRX), and Allergan PLC (NYSE: AGN). Companies in the generic pharmaceuticals sector make drugs that are offered cheaper than name-brand pharmaceuticals once patents for the more expensive drugs lapse.
Market Realist•3 months agoWhy Axovant Sciences Stock Rose in Week Ended June 8
Axovant Sciences (AXON) stock rose 150% in the week of June 1–8. Over the last quarter, Axovant Sciences stock has risen 192.7%. On June 6, Axovant Sciences entered into a licensing agreement for worldwide rights to develop and sell Oxford BioMedica’s OXB-102 investigational gene therapy for the treatment of Parkinson’s disease.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of ADMS earnings conference call or presentation 3-May-18 8:30pm GMT
Q1 2018 Adamas Pharmaceuticals Inc Earnings Call
- Benzinga•5 months ago
Benzinga's Daily Biotech Pulse: Portola Receives FDA Nod, Mallinckrodt Gets Thumbs Down
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling the Peaks (Stocks hitting 52-week highs on May 3) ABIOMED, Inc. (NASDAQ: ABMD ) (reported better-than-expected ...
